Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $12

Benzinga Newsdesk www.benzinga.com Negative 82.6%

Neg 82.6% Neu 0% Pos 0%

Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $13 to $12.